(Reuters) – British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company’s hepatitis B therapy.
Exclusive rights to the therapy, JNJ-3989, which Arrowhead Pharmaceuticals initially developed and licensed to Janssen in 2018, will fuel the expansion of GSK’s own hepatitis B treatment, bepirovirsen, it said.
(Reporting by Eva Mathews in Bengaluru; Editing by Shinjini Ganguli)
